The aim of this study was to model the in vivo kinetic consequences of mechanism-based inhibition (MBI) of CYP2D6 by 3,4 methylenedioxymethamphetamine (MDMA, ecstasy). A model with physiologically-based components of drug metabolism was developed, taking account of change in the hepatic content of active CYP2D6 due to MBI by MDMA. Based on the in vitro information, plasma concentration time profiles of MDMA after various doses were computed and compared with reported observations. The analysis suggested that a typical recreational MDMA dose could inactivate most hepatic CYP2D6 within an hour, and the return to a basal level of CYP2D6 could take at least 10 days. Thus, the genetic polymorphism of CYP2D6 and coadministration of CYP2D6 inhibitors may have less impact on MDMA pharmacokinetics and the risk of acute toxicity than previously thought. This is consistent with clinical observations that indicate no obvious link between inherited CYP2D6 deficiency and acute MDMA intoxication.
Back T , Fogel D B , Michalewics Z (1997) Handbook of Evolutionary Computation. Institute of Physics Pub., Oxford University Press, Bristol .
2.
Bertelsen K M , Venkatakrishnan K , von Moltke L L , Obach R S , Greenblatt D J (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine . Drug Metab Dispos31: 289–293 .
3.
de la Torre R , Farre M (2004) Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans . Trends Pharmacol Sci25: 505–508 .
4.
de la Torre R , Farre M , Ortuno J , Mas M , Brenneisen R , Roset P N , Segura J , Cami J (2000) Non-linear pharmacokinetics of MDMA (‘ecstasy’) in humans . Br J Clin Pharmacol49: 104–109 .
5.
Delaforge M , Jaouen M , Bouille G (1999) Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450 . Particular involvement of CYP 2D. Environ Toxicol and Pharmacol7: 153–158 .
6.
Deray G , Bochet M , Katlama C , Bricaire F (1998) Nephrotoxicity of ritonavir . Presse Medicale27: 1801–1803 .
7.
Farre M , de la Torre R , Oathuna M B , Roset PN , Peiro A M , Torrens M , Ortuno J , Pujadas M , Cami J (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics . Psychopharmacology (Berl)173: 364–375 .
8.
Gilhooly T C , Daly A K (2002) CYP2D6 deficiency, a factor in ecstasy related deaths?Br J Clin Pharmacol54: 69–70 .
9.
Goldberg D E (1989) Genetic Algorithms in Search, Optimisation, and Machine Learning. Addison Wesley, Wokingham .
10.
Green A R , Mechan A O , Elliott J M , O'Shea E , Colado M I (2003) The pharmacology and clinical pharmacology of 3,4-methylene dioxymethamphetamine (MDMA, ‘ecstasy’) . Pharmacol Rev55: 463–508 .
11.
Henry J A , Hill I R (1998) Fatal interaction between ritonavir and MDMA . Lancet352: 1751–1752 .
12.
Henry J A , Jeffreys K J , Dawling S (1992) Toxicity and deaths from 3,4 methylenedioxymethamphetamine (Ecstasy) . Lancet340: 384–387 .
13.
Hesse L M , von Moltke L L , Shader R I , Greenblatt D J (2001) Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion . Drug Metab Dispos29: 100–102 .
14.
Heydari A , Yeo K R , Lennard M S , Ellis S W , Tucker G T , Rostami-Hodjegan A (2004) Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine . Drug Metab Dispos32: 1213–1217 .
15.
Holland J H (1975) Adaptation in Natural and Artificial Systems. University of Michigan Press, Ann Arbor, MI .
16.
Ingelman-Sundberg M , Oscarson M , McLellan R A (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment . Trends Pharmacol Sci20: 342–349 .
17.
Jones D C , Duvauchelle C , Ikegami A , Olsen C M , Lau S S , de la Torre R , Monks T J (2005) Serotonergic neurotoxic metabolites of ecstasy identified in rat brain . J Pharmacol Exp Ther313: 422–431 .
18.
Kreth K P , Kovar K A , Schwab M , Zanger U M (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of ‘Ecstasy’-related designer drugs . Biochem Pharmacol59: 1563–1571 .
19.
Lappin G , Garner R C (2003) Big physics, small doses: the use of AMS and PET in human microdosing of development drugs . Nature Rev Drug Discov2: 233–240 .
20.
O'Donohoe A , O'Flynn K , Shields K , Hawi Z , Gill M (1998) MDMA toxicity: no evidence for a major influence of metabolic genotype at CYP2D6 . Addiction Biol3: 309–314 .
21.
Ramamoorthy Y , Yu A M , Suh N , Haining R L , Tyndale R F , Sellers E M (2002) Reduced(+/-)-3,4-methylenedioxymethamphetamine (‘Ecstasy’) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro . Biochem Pharmacol63: 2111–2119 .
22.
Renwick A B , Watts P S , Edwards R J , Barton P T , Guyonnet I , Price R J , Tredger J M , Pelkonen O , Boobis A R , Lake B G (2000) Differential maintenance of Cytochrome P450 enzymes in cultured precision-cut human liver slices . Drug Metab Dispos28: 1202–1209 .
23.
Schwab M , Seyringer E , Brauer R B , Hellinger A , Griese E U (1999) Fatal MDMA intoxication . Lancet353: 593–594 .
24.
Segura M , Farre M , Pichini S , Peiro A M , Roset P N , Ramirez A , Ortuno J , Pacific R , Zuccaro P , Segura J , de la Torre R (2005) Contribution of Cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe . Clin Pharmacokinet44: 649–660 .
25.
Silverman R B (1988) Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology. CRC Press, Boca Raton, FL .
26.
Tucker G T , Lennard M S , Ellis S W , Woods H F , Cho A K , Lin L Y , Hiratsuka A , Schmitz D A , Chu T Y Y (1994) The demethylenation of methylenedioxymethamphetamine (ecstasy) by debrisoquine hydroxylase (CYP2D6) . Biochem Pharmacol47: 1151–1156 .
27.
Valentin J (2002) Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. Pergamon, Oxford .
28.
von Moltke L L , Durol A L B , Duan S X , Greenblatt D J (2000) Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole . Eur J Clin Pharmacol56: 259–261 .
29.
von Moltke L L , Greenblatt D J , Grassi J M , Granda B W , Duan S X , Fogelman S M , Daily J P , Harmatz J S , Shader R I (1998) Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir . J Clin Pharmacol38: 106–111 .
30.
Wilson Z E , Rostami-Hodjegan A , Burn J L , Tooley A , Boyle J , Ellis S W , Tucker G T (2003) Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver . Br J Clin Pharmacol56: 433–440 .
31.
Wu D F , Otton S V , Inaba T , Kalow W , Sellers E M (1997) Interactions of amphetamine analogs with human liver CYP2D6 . Biochem Pharmacol53: 1605–1612 .
32.
Yang J , Rostami-Hodjegan A (2004) Metabolic kinetic constants when drugs cause mechanism-based inhibition of their own metabolism . Drug Metab Rev36 (suppl. 1): 292-292 .
33.
Yang J , Jamei M , Yeo K R , Rostami-Hodjegan A , Tucker G T (2005) Kinetic values for mechanism-based inhibition: assessment of bias introduced by the conventional experimental protocol . Eur J of Pharm Sci26: 334–340 .
34.
Yeo K R , Rostami-Hodjegan A , Tucker G T (2004) Abundance of cytochrome P450 in human liver: a meta-analysis . Br J Clin Pharmacol57: 687–688
